 |
인쇄하기
취소
|
Dong-A looks to future with new drugs
The two drug candidates of Dong-A Pharmaceutical Co. are expected to bolster its stock prices in the near future, according to market analysts.
The company said that its pipeline drugs - functional dyspepsia drug (DA-9701) and anti-infective agent (DA-7218) – are now under Phase 3 clinical trial, with a big sales potential in the world’s pharmaceutical market.
DA-7218 has been shown to be...
The company said that its pipeline drugs - functional dyspepsia drug (DA-9701) and anti-infective agent (DA-7218) – are now under Phase 3 clinical trial, with a big sales potential in the world’s pharmaceutical market.
DA-7218 has been shown to be...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.